1991; Letterio & Bottinger 1998) . It is perhaps surprising, therefore, that the majority of studies only examined the role of TGF-b1 in tumorigenesis, even though isoform-specific differences have been identified (Laverty et al. 2009 ).
Squamous cell carcinoma (SCC) is the most common epithelial malignancy in man, and SCC of the skin is a significant world health problem. Early studies using the mouse model of skin carcinogenesis were pioneering in our understanding of the role of TGF-b1 in cancer and demonstrated that TGF-b1 promoted metastasis in late stage SCC (Cui et al. 1996; Portella et al. 1998) . However, a number of studies, including our own, have failed to demonstrate a tumour promoting role for TGF-b1 in the development and progression of SCC in the skin of humans. For example, Gold et al. (2000) showed in tumours derived from cells in the HaCaT model of human epidermal tumour progression that TGF-b1 was associated with a more differentiated state,
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and we demonstrated that expression of a dominant-negative TbRII in cells representing the later stages of tumour progression in the HaCaT model inhibited metastasis (Ganapathy et al. 2010) . Whether the discrepancies in the apparent role of TGF-b1 between mouse and human models are because of fundamental differences between murine and human cells or simply represent differences in experimental approach is uncertain. Interestingly, Gold et al. (2000) also demonstrated that large, invasive SCCs expressed high levels of TGF-b2, particularly at the invasive front, suggesting that TGF-b2 might be more likely to promote tumour invasion than TGF-b1.
The Ha-ras transformed clonal cell line, I-7, formed slowly growing and encapsulated keratinizing cysts when transplanted subcutaneously into athymic mice (Fusenig & Boukamp 1998) . In surface transplants, I-7 cells gave rise to slightly dysplastic but keratinizing epithelia in which TGFb1 expression was restricted to the upper differentiated layers, and TGF-b2 showed weak cytoplasmic expression in the upper epithelial layers (Gold et al. 2000) . In the present study, we examined the effect of overexpressing either TGFb1 or TGF-b2 on the behaviour of I-7 cells in organotypic invasion assays, and we demonstrate that overexpression of both isoforms resulted in a more invasive phenotype in vitro. In addition, transplantation of TGF-b1 overexpressing I-7 cells to the floor of the mouth in athymic mice resulted in faster growing, larger, weakly metastatic tumours, as compared to small, non-metastatic tumours formed after the transplantation of control cells. Our data show that both TGF-b1 and TGF-b2 can function as tumour promoters in early human SCC.
Materials and methods

Cell lines and culture
The human keratinocyte cell clone, I-7 (a kind gift from Prof. Norbert Fusenig, Heidelberg, Germany), was created following the transfection of the immortalized from normal adult skin cell line, HaCaT, with mutant c-Ha-ras and subsequent selection with G418. I-7 also contains mutant p53, a common initiating event in human skin cancer and is representative of early stage skin SCC in the HaCaT model of tumour progression. The series of cell lines derived from HaCaT show increasing tumorigenic ⁄ metastatic potential following subcutaneous ⁄ tail vein transplantation to athymic mice and are an excellent model of the multistep processes of epidermal transformation (Fusenig & Boukamp 1998) .
I-7 cells were cultured in standard medium (SM) consisting of Dulbecco's modified Eagle's medium (DMEM):Ham's F12 (1:1; BioWhittaker) contains 10% (v ⁄ v) foetal bovine serum (FBS), 0.5 lg ⁄ ml hydrocortisone and 400 lg ⁄ ml geneticin sulphate (G418; PAA laboratories, Yeovil, UK). The amphotrophic packaging cell line AM-12 and fibroblast cell line ICRF 23 (both kind gifts from Dr John Marshall, UCL) were cultured in DMEM containing 10% (v ⁄ v) FBS, supplemented with 0.6 mg ⁄ ml l-glutamine or DMEM, containing 20% (v ⁄ v) foetal clone III (Hyclone) and l-glutamine 0.3 lg ⁄ ml, respectively.
Overexpression of TGF-b
TGF-b1 cDNA was subcloned in a sense orientation into pIRESpuro2 (Takahara Bio Europe ⁄ Clontech Saint-Germainen-Laye, France) from pcDNA3-TGF-b1, the preparation of which has been described previously (Davies et al. 1997) . I-7 cells at 30-50% confluent were transfected with 10 lg pIRES-puro or pIRES-TGF-b1 DNA using Fugene-6 reagent (Roche, Burgess Hill, UK) according to the manufacturer's instructions. Stable transfectants were selected in medium containing 0.5 lg ⁄ ml puromycin and cloned to isolate colonies overexpressing high quantities of TGF-b1.
The plasmid pRK5-b2 (encoding the full length coding sequence for the human TGF-b2 precursor; Graycar et al. 1989 ) was used as a template for gene amplification by PCR. The primers 5¢TTCTGTTGGGCATTGAC-3¢ (left primer) and 5¢-GCATCATCGTTGTCGTC-3¢, deduced from the published sequence, were used to amplify the full coding sequence of TGF-b2. The 1.6 Kb PCR product was TA-cloned into pCR4-TOPO (Invitrogen, Paisley, UK), excised with EcoR1 and then subcloned in a sense orientation into the mammalian expression vector pBABE-puro (a kind gift from Dr John Marshall, UCL). The amphotrophic packaging cell line AM-12 was transfected with pBABE-puro-TGF-b2 or empty vector using Fugene-6 as described previously and stable transfectants selected in medium containing 3.5 lg ⁄ ml puromycin. I-7 cells were transduced with conditioned media (CM) collected from stably transfected AM-12 cells as described previously (Davies et al. 2005) . Stably transduced cells were selected in medium containing 0.5 lg ⁄ ml puromycin, expanded and cloned to isolate colonies overexpressing high quantities of TGF-b2.
ELISA
Clones were grown to 50% confluence, incubated in serumfree medium consisting of DMEM:Ham's F12 (1:1) containing 0.5 lg ⁄ ml hydrocortisone and 200 lg ⁄ ml BSA (Sigma; SigmaAldrich, Dorset, UK SFM + BSA) for 24 h during which the media were replaced three times and then incubated for a further 24 h in a reduced volume of SFM + BSA. CM was collected into siliconized tubes and cell numbers were determined by counting. The total autocrine production of TGF-b1 or TGF-b2 in CM following acid activation was determined using the relevant Quantikine immunoassay kit (R&D Systems, Abingdon, UK). The quantity of total TGF-b1 ⁄ 2 in each sample was expressed as pg TGF-b ⁄ 24 h ⁄ 10 6 cells. Clones expressing the highest levels of TGF-b1 and TGF-b2 were selected for further study and are listed in Table 1 .
Proliferation rates and response to TGF-b
In experiments to determine growth rates, cells were seeded in 60 mm dishes at 3 · 10 4 cells per dish in a standard medium supplemented with G418 and puromycin. Medium was replenished every 3 days and triplicate dishes were counted at days 4, 7 and 10.
In experiments to examine growth inhibitory response to TGF-b, cells were grown to 20-40% confluence in a standard medium containing antibiotics as appropriate. Cells were treated daily for a total period of 72 h (three treatments) with TGF-b1 (R&D systems; 1 ng ⁄ ml) or TGF-b vehicle control (4 mM HCl, 0.1% (w ⁄ v) BSA) in DMEM:Ham's F12 (1:1) containing 1% (v ⁄ v) FBS and 0.5 lg ⁄ ml hydrocortisone and the cell number determined by counting after 72 h.
Organotypic invasion assays
Organotypic cultures with an air-tissue interface were prepared, as described previously (Nystrom et al. 2005) . Briefly, gels comprising a 50:50 mixture of Matrigel (Becton-Dickinson, Oxford, UK) and type I collagen (Upstate) containing 1% (v ⁄ v) FBS, 1% (v ⁄ v) Hank's Balanced Salt Solution (HBSS) and 1 · 10 6 ⁄ ml ICRF 23 fibroblasts were prepared in cell culture inserts (pore size 3 lm) placed in six-well biocoat plates (Becton Dickinson). After 1 h, sterile glass rings were placed on the gels, and 45 min later DMEM, containing 20% (v ⁄ v) foetal clone III (Hyclone), l-glutamine 0.3 lg ⁄ ml (FCM) was added to the wells to the level of the insert bases and inside the glass rings. After a further 20 h, the FCM in the glass rings was replaced by 1 ml FAD medium [DMEM: Hams F12 (3:1), 5% FBS(v ⁄ v), 5 lg ⁄ ml insulin, 10 ng ⁄ ml hEGF, 24 ng ⁄ ml adenine, 0.4 lg ⁄ ml hydrocortisone, 100 U ⁄ ml penicillin, 10 lg ⁄ ml streptomycin, 250 ng ⁄ ml amphotericin B] containing 1 · 10 6 I-7 cells. After a further 24 h, the rings and the media were removed and the media in the wells replaced with rFAD [DMEM:Hams F12 (3:1), 10% FBS, 50 lg ⁄ ml l-ascorbic acid, 100 U ⁄ ml penicillin, 10 lg ⁄ ml streptomycin, 250 ng ⁄ ml amphotericin B]. After 7-14 days, the gels were fixed in formal-saline, embedded in a solution containing 1% (v ⁄ v) agarose, 10% (v ⁄ v) formol saline and processed to paraffin. Sections (2 lm) were stained with H&E. Cells were assessed to have invaded only if they had penetrated deep in the Matrigel.
Transplantation studies
5 · 10 6 cells in 10 ll serum-free medium were injected into the floor of the mouth of 4-6-week-old athymic mice (nu ⁄ nu), using techniques described previously (Davies et al. 1997) . Mice were examined daily and sacrificed by cervical dislocation after 50 days. Tissues were processed routinely and sections stained with haematoxylin and eosin (H&E). Local spread of the primary tumours to the bone, blood and lymphatic system, and metastatic dissemination to the lungs and lymph nodes were determined by a specialist oral and maxillofacial pathologist (JE). Large tumours occupied more than 50% of the tongue, medium 25-50% and small <25%. These experiments were approved by the UK Home Office and carried out by Prof S Prime (personal licence PCD 3002302, project licence PL 3002084).
Immunohistochemistry
Dewaxed, rehydrated paraffin embedded tissue sections (2 lm) were treated with 3% (v ⁄ v) hydrogen peroxide (15 min) to block endogenous peroxide activity. Immunohistochemical staining was carried out using standard techniques and reagents. Details of the antibody concentrations and antigen retrieval methods are given in Table 2 . Staining controls included omission of the primary antibody and substitution of the primary layer with a monoclonal antibody of irrelevant specificity but similar immunoglobulin isotype and were consistently negative. The percentage of cells positive for the protein of interest was counted in a minimum of five random fields in a minimum of five tumours formed in the transplantation studies, or three random fields in a minimum of three organotypic cultures.
Statistical analysis
Statistical analyses were performed using the Student's t-test, one-way anova with Tukey's multiple comparison or v 2 test as appropriate, with P < 0.05 taken to be statistically significant.
Results
Expression of TGF-b1 ⁄ b2 and TGF-b responses in I-7 cells and transfectants
Total levels of TGF-b produced by I-7 parental cells, vector, TGF-b1 and TGF-b2 expressing clones were determined by isoform-specific ELISA. Vector-only controls secreted similar amounts of TGF-b1 and TGF-b2 as parent I-7 cells. Clones transfected with TGF-b1 expressed significantly (P < 0.05) more ligand than parental or vector control cells, and clones transduced with TGF-b2 expressed significantly (I-7b2C2; P < 0.01) or markedly (I-7 b2C5; P = 0.0618) more ligand than parent or vector controls (Figure 1a,b) .
The growth inhibitory response of the transfected cells to TGF-b was retained, and the proliferation of cells overexpressing TGF-b1 or TGF-b2 was inhibited by exogenous TGF-b1 to a similar extent as controls (Figure 1c,d) . In growth assays in the absence of exogenous ligand, there was no significant difference between the number of parental I-7 or ppC3 vector control cells at any time point. However, cell lines that overexpressed TGF-b1 grew markedly more slowly than vector controls (Figure 1e ). After 7 days, the cell yield for TGF-b1 overexpressing clones was significantly (P < 0.0005) less than that of the yield for either the parental or vector control cell lines. TGF-b2 overexpressing clones grew at a similar rate to control cells (Figure 1f) . The differences between the growth rates for the TGF-b1 and TGF-b2 overexpressing cells are consistent with the observation that TGF-b1 is a more potent inhibitor of cell growth than TGFb2 (Fahey et al. 1996) , but may also reflect the fact that we consistently detected some active TGF-b1 in the CM of TGF-b1 overexpressing cells by ELISA, but were unable to detect active TGF-b2 in every experiment undertaken (data not shown).
(e) (f) Figure 1 (a,b) production of TGF-b1 or TGF-b2, respectively, as determined by ELISA, total ligand production is expressed as pg produced in 24 h by 1 · 10 6 cells. (c,d) Growth inhibitory response to TGF-b1 of I-7b1 or I-7b2 clones, respectively. (e,f) Growth characteristics of a monolayer culture of parental, vector and I-7b1 clones or I-7b2 clones, respectively. Cells were counted at 4 and 7 days after seeding. Results are the means of values from conditioned media collected from at least three independent experiments (a,b) or representative of three independent experiments (c-f) ± SD. *Produced significantly (P < 0.05) more ligand than parent or vector controls.
Exogenous TGF-b1 did not induce an epithelial to mesenchymal transition (EMT) in parent I-7 cells, as determined by the delocalization of E-cadherin from a cell membrane to a cytoplasmic location, and there was no evidence of an EMT in transfected ⁄ transduced cells (data not shown).
Invasion in organotypic cultures
To determine whether elevated levels of endogenous TGF-b1 or TGF-b2 altered the invasive capacity of I-7 cells, we used a three-dimensional organotypic model that has been used previously to study tumour cell invasion in a physiologically relevant manner (Nystrom et al. 2005; Yap et al. 2009 ). I-7 cells that overexpressed either TGF-b1 or TGF-b2 were markedly more invasive than controls, with islands of cells penetrating deeper into the matrix (Figure 2a) for each isoform, both overexpressing clones behaved in a similar way. Tissue sections from the TGF-b1 experiment were stained with Ki67 and the results showed that the percentage of TGF-b1 overexpressing cells that expressed Ki67 was significantly higher than in control cultures (Figure 2b ; P < 0.5), indicating that the invading cells were also proliferating at a higher rate than controls.
Functional consequences in vivo
To investigate whether the more aggressive behaviour of the TGF-b overexpressing cells was maintained in vivo, TGF-b1 overexpressing cells were transplanted to the floor of the mouth of athymic mice; tumorigenicity and metastases are shown in Table 3 . Tumour uptake was similar in all cases (approx. 100%). There was no difference in the size of the tumours formed by I-7 and I-7ppC3; however, the tumours formed by each clone were significantly bigger than those formed by either I-7 parental cells (P < 0.0001 for both clones) or I-7ppC3 (I-7ppC3 vs. I-7b1C3, P < 0.0001; I- To investigate why the tumours formed by TGF-b1 overexpressing cells were larger than controls, the expression of pSmad2 and Ki67 was examined in the tumours by immunohistochemistry. Levels of nuclear pSmad2 staining (a marker of active TGF-b signalling) were high in all tumours, but there was no difference the percentage of cells that stained for nuclear pSmad2 (Figure 4) . However, similar to the organotypic invasion cultures, the percentage of cells staining positive for Ki67 in the tumours containing TGF-b1 overexpressing cells was significantly (I-7b1C3 vs. ppC3, P < 0.05; I-7b1C3 vs. I-7, P < 0.0001; I-7b1C6 vs. I-7, P < 0.01) or markedly (I-7b1C6 vs. I-7ppC3) higher than in tumours derived from control or vector-only transfected cells ( Figure 5 ).
Discussion
The role of TGF-b in carcinogenesis is extremely complex, and this complexity arises from the fact that the actions of the ligand are context dependent (Meulmeester & ten Dijke 2011) and also because differences between the TGF-b isoforms have been documented (Laverty et al. 2009) . A number of strategies aimed at targeting the TGF-b pathway are currently being developed as cancer therapeutics (Korpal & Kang 2010) , but, before these approaches can be fully utilized, a more comprehensive understanding of how TGF-b regulates tumour behaviour in common human cancer types is required. The present study examined the effects of overexpressing TGF-b1 or TGF-b2 in cells representing the early stages of human epidermal SCC.
To study the effects of TGF-b on early stage human epidermal SCC, we used the I-7 cell line which was one of a series of cell lines generated following transfection of HaCaT cells with mutant Ha-Ras and has been shown to be representative of non-invasive, preneoplastic stages of human SCC (Fusenig & Boukamp 1998; Gold et al. 2000) . To ectopically express TGF-b1, I-7 cells were transfected with latent TGF-b1 cDNA in the plasmid pIRESpuro2. For TGF-b2, we needed to use a more efficient retroviral transduction approach, as we did not achieve sufficient expression with pIRESpuro2. Nevertheless, both expression systems resulted in clones that produced approximately twice as much ligand as control (vector only) cells. Levels of bioactive ligand in vitro were measured in non-activated samples of CM and the levels varied from low to moderate, although generally higher in the TGF-b1 compared to the TGF-b2 expressing cells (data not shown). We used latent TGF-b to reflect the fact that cells secrete latent ligand in vivo that must be activated. We show that I-7 cells retain a partial response to the growth inhibitory effects of TGF-b and cells that overexpressed either TGF-b1 or TGF-b2 retained this response, but showed no evidence of EMT. However, both the TGF-b1 and the TGF-b2 overexpressing cells were more invasive in organotypic assays, compared to control cell lines. Additionally, when the TGF-b1 overexpressing cells were transplanted to the floor of the mouth of athymic mice, the tumours formed were larger than controls and showed some evidence of metastasis and local bone invasion, an effect that was absent in controls. Collectively, these data demonstrate that overexpression of either TGF-b1 or TGF-b2 in I-7 early stage human SCC cells results in a more invasive and aggressive phenotype. Further, Ki67 staining in tissue sections from the organotypic invasion assays and in vivo tumours containing the TGF-b1 overexpressing cells was higher than those containing control cells, showing that these cells were not only more invasive but, also, had a higher rate of proliferation.
Few studies to date have investigated the role of TGF-b2 in carcinogenesis, and none have examined its expression in human clinical SCC, but this isoform has been shown to be overexpressed in gastric and colon carcinomas with increasing expression correlating with stage and poor prognosis, respectively, (Tsamandas et al. 2004; Vagenas et al. 2007) . The increase in TGFb2 expression seen from stage I -II in gastric cancer supports a role for this isoform in early stage carcinogenesis. In addition, a polymorphism in the promoter of the TGBb2 gene that increases the expression of the isoform and correlates with lymph node metastasis in breast cancer patients has been identified (Beisner et al. 2006) , supporting a role for TGF-b2 in inducing local invasion. Levels of expression of TGF-b1 in human clinical SCC have been examined previously, and similar to TGF-b2 in gastric cancer, it has been demonstrated that expression of the ligand increases progressively during carcinogenesis from normal skin to SCC (normal < Actinic Keratoses < Carcinoma in situ < SCC; Han et al. 2005) . These authors also observed an inverse correlation between TGF-b1 expression and both nuclear pSmad2 and TbRII levels and suggested that overexpression of TGF-b1 enhances tumorigenicity in SCC by down-regulating TbRII, and subsequently pSmad2, resulting in an escape from ligand-mediated growth control. Previous studies in our laboratory, however, have demonstrated that levels of pSmad2 are high in clinical samples of well-differentiated human SCCs (Ganapathy et al. 2010) , and in the present study, levels of pSmad2 remained high in tumours formed by TGF-b1 overexpressing clones. Our data suggest that proliferation in these tumours is not enhanced as a result of decreased signalling because of a down-regulation of TbRII, although the mechanisms to account for the increased growth rate in TGF-b overexpressing tumours in vivo are unclear. In addition to activating the canonical Smad pathway, TGF-b can also activate Smadindependent pathways, such as the activation of Erk via a mechanism that involves Shc (Lee et al., 2007; Zhang 2009 ). However, it is not known whether the overexpression of TGF-b in I-7 cells in the present study can enhance signalling downstream of oncogenic Ras. It is also possible that the enhanced proliferation of the TGF-b1 overexpressing cells seen in the organotypic assays and in vivo could be due to indirect effects, such as TGF-b-induced expression of mitogenic growth factors in the fibroblasts or tumour microenvironment. In support of our observations, elevated rates of proliferation have been reported in tumours formed by breast cancer cells that overexpressed TGF-b1 (Tobin et al. 2002) , and these cells also grew more slowly than controls in vitro. In addition, Tobin et al. (2002) showed that expression of a dominant-negative TbRII (dnTbRII) construct in the TGF-b overexpressing breast cancer cells reduced the rate of proliferation of tumours, demonstrating that in these tumours, TbRII expression was required to maintain enhanced growth rates in vivo. Collectively, these data highlight the importance of using cell systems that closely reflect the in vivo situation when examining the effect of overexpressing TGF-b on tumour cell behaviour.
There is accumulating evidence for a tumour promoting role for TGF-b in the later stages of cancer, but there is little evidence to suggest that TGF-b switches from tumour suppressor to tumour promoter early in disease progression. Epithelial to mesenchymal transition is known to be associated with a more invasive and aggressive phenotype (Thiery et al. 2009 ), and we have shown previously that exogenous TGF-b1 can cooperate with mutant Ras to induce an EMT in human epidermal keratinocytes (Davies et al. 2005) . However, in the present study, overexpression of either TGF-b1 or TGF-b2 in cells that represent early stage human SCC resulted in a more aggressive ⁄ invasive phenotype without evidence of EMT, either in organotypic cultures or tumours formed in athymic mice. So, the question remains as to the mechanism(s) responsible for our observations. The molecular mechanisms that underlie the switch of TGF-b from tumour suppressor to promoter are still largely unclear. Hannigan et al. (2010) recently reported that methylation of the DAB2 promoter enabled TGF-b to promote cell motility in vitro and enhance tumour growth in vitro in SCC cells, an effect that was associated with elevated levels of TGF-b2. The status of the DAB2 promoter in I-7 cells is unknown, but it seems unlikely that it is methylated because I-7 was derived from HaCaT, which was derived from normal skin (Fusenig & Boukamp 1998) . Possibly, a more likely explanation comes from the observation that TGF-b acts in concert with oncogenic Ras and mutant p53 to antagonize the function of p63, resulting in an increase in TGF-b-induced migration, invasion and metastasis (Adorno et al. 2009 ). More specifically, Adorno et al. (2009) used HaCaT cells (which contain mutant p53) to show the formation of a TGF-b-induced ternary complex between endogenous receptor Smads (R-Smads), mutant p53 and p63. Further, they showed that the formation of this complex is dependent upon oncogenic Ras and results in tumour promotion. In our study, we used I-7 cells, which contain oncogenic Ras, which in TGF-b overexpressing cells would result in ternary complex formation and inhibition of p63 function, giving rise to a more aggressive phenotype. The formation of a TGF-b-induced ternary complex between endogenous RSmads, mutant p53 and p63 might also explain our previous findings that expression of a dnTbRII in late stage SCC cells results in tumour promotion (Ganapathy et al. 2010) , results that seemingly contrast with the results of the present study. However, in a situation where TGF-b signalling is attenuated, normal ligand levels would likely be insufficient to promote the formation this complex, leaving the function of p63 unopposed, such that ligand induction of metastasis would be inhibited.
In summary, the results of the present study demonstrate that elevated expression of either TGF-b1 or TGF-b2 in cells that represent the early stages in the development of human SCC results in a more aggressive phenotype. These findings highlight the complexity of the role played by TGF-b in SCC and carcinogenesis in general. A full understanding of the mechanisms underlying how TGF-b influences tumour development and progression will be required before therapeutic targeting of the TGF-b pathway can be used.
